BMRN - belongs to the medical industry.
Biomarine is an American biotechnology company focused on enzyme replacement therapy.
On August 1, it reported financial results for the second quarter of 2019. Revenue for the quarter was $ 387.8 million, up 4% from $ 372.8 million for the same period last year. The net loss was $ 37.4 million, compared to a net loss of $...
Morningstar weekly highlights set Biomarin Pharmaceuticals with an amazing $119 fair price value (50% above current price).
Rating: 4 stars
Uncertainty rating: Medium
Moat: Narrow
The stock price just bounced from its major support yesterday and now it is going to test its resistance. If it could cross above $87.5 area with high volume, there is a probability the price would reach $98 or even $106.
Today we gonna look at the pharmaceutical company, as a potential new giant trend on the stock market. NASDAQ:BMRN laying on the strong support line near $87.87 and can move up suddenly. My recommendation:
1. Buy now around 87.87
2. Take profit: 109.45
3. SL: 78.68
Risk/Reward - 2.39, potential profit - 24,6%
Blue line: Channel on weekly
Red line: Daily overall pattern
Purple: Daily Micro pattern
Its been in an ascending wedge for a while now;
I think this is ready to follow the blue line and make a slow descent towards 80s
Looks like stuck in coil with indicators at week, 1 month, and 3 month still not showing upward trend. Possibly coincides with april/may convergence. Look for break above $100.
Biomarin Pharmaceutical (BMRN) is in a huge triangle pattern with double bottom stochastic divergence on trend line support. I highlighted recent divergences and you can see the kind of move this stock makes off of the signal.
Be patient, and get in on the way up.
Buy: 84.23
Target: 86.49 - 90.14 (2.69 - 7.02%)
jbzstocks.com
@jbzstocks
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.
This website uses cookies to ensure you get the best experience on our website. To learn more about cookies, including how to control cookies, please read our Cookies Policy.
BMRN
![BMRN: [BMRN] It's starting phase 3?](https://s3.tradingview.com/j/JsuVAiWM_mid.png "[BMRN] It's starting phase 3?")
